fingolimod hydrochloride has been researched along with apyrase in 2 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (apyrase) | Trials (apyrase) | Recent Studies (post-2010) (apyrase) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 1,997 | 16 | 833 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, HA; Muls, N; Sindic, CJ; van Pesch, V | 1 |
| Álvarez-Sánchez, N; Carrillo-Vico, A; Cruz-Chamorro, I; Díaz-Sánchez, M; Guerrero, JM; Lardone, PJ | 1 |
2 other study(ies) available for fingolimod hydrochloride and apyrase
| Article | Year |
|---|---|
Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Topics: Antigens, CD; Antigens, CD19; Apyrase; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; CD4-Positive T-Lymphocytes; Cytochrome P-450 CYP1B1; Cytokines; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Immunosuppressive Agents; Multiple Sclerosis; Receptors, Aryl Hydrocarbon; T-Lymphocytes, Regulatory | 2014 |
Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients.
Topics: Adenosine Triphosphatases; Adult; Antigens, CD; Apyrase; Cells, Cultured; Female; Fingolimod Hydrochloride; Flow Cytometry; Glatiramer Acetate; Humans; Leukocytes, Mononuclear; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peripheral Blood Stem Cells; T-Lymphocytes, Regulatory | 2019 |